GAITHERSBURG, Md. -- Antex Biologics Inc., through its AntexPharma subsidiary, continues to explore the potential effectiveness of its novel anti-infective compounds in preventing and destroying pathogenic bacteria biofilms of national concern. Biofilms, a form in which bacteria increase their virulence and resistance are not only a problem in hospital acquired infections, but are also of major concern in food and environmental infections.
The company announced earlier that AP158 and several of its analogues were effective in destroying methicillin resistant Staphylococcus aureus biofilms and were active against Bacillus anthracis. Based on these results, the compounds have been tested against Listeria monocytogenes an important foodborne pathogen. The compounds were very active in destroying the biofilm and killing the bacteria. Listeria has been recognized as a human pathogen since 1929, but recent foodborne outbreaks and ensuing concern about food safety has brought this bacteria into the spotlight. This pathogen causes a higher rate of hospitalization than any other foodborne pathogen. Ninety-five percent of the individuals who acquire listeriosis are hospitalized and this disease is the leading cause of death from foodborne pathogens. Listeria is a very difficult pathogen to control from an environmental perspective. Further work is planned to evaluate Antex proprietary compounds for use in controlling and eliminating this pathogen in food processing environments.
Based on the biofilm results to date and the earlier reported results of the U.S. Army's testing of AP158 and its analogues against Anthrax, the Company plans to evaluate the compounds against biofilms of Bacillus anthracis (anthrax), Clostridium botulinum (botulism) and Yersinia pestis (plague). Reported studies indicate that the biofilms of these pathogens are important in environmental survival and transmission. These pathogenic bacteria along with Listeria and Shigella are on the Category A and B Bioterrorism Agents list.
Several of these agents share common characteristics including their ability to survive in the environment. Anthrax has an important place in infectious disease history; it was the first human disease attributed to a specific infectious agent. Clostridium botulinum is a group of bacteria that produce a potent neurotoxin that causes paralysis. Plague, an acute and fatal disease, is an ancient disease with a long record of devastating and disastrous pandemics, and like anthrax and botulism, can last for long periods of time in the soil.
Antex Biologics, and its wholly owned subsidiary, AntexPharma, is a biopharmaceutical company committed to developing and marketing new products to prevent and treat infections and related diseases. The company maintains strategic alliances with GlaxoSmithKline, Aventis Pasteur and the US Department of Defense.
Source: Antex Biologics Inc.
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Tackling Health Care-Associated Infections: SHEA’s Bold 10-Year Research Plan to Save Lives
December 12th 2024Discover SHEA's visionary 10-year plan to reduce HAIs by advancing infection prevention strategies, understanding transmission, and improving diagnostic practices for better patient outcomes.
Environmental Hygiene: Air Pressure and Ventilation: Negative vs Positive Pressure
December 10th 2024Learn more about how effective air pressure regulation in health care facilities is crucial for controlling airborne pathogens like tuberculosis and COVID-19, ensuring a safer environment for all patients and staff.
Pioneering Advances in Sterilization: The Future of Infection Control
November 28th 2024Germitec, STERIS, ASP, and Zuno Medical are pioneering sterilization advancements with groundbreaking technologies that enhance SPD workflows, improve patient safety, and redefine infection control standards.
Infection Intel: Revolutionizing Ultrasound Probe Disinfection With Germitec's Chronos
November 19th 2024Learn how Germitec’s Chronos uses patented UV-C technology for high-level disinfection of ultrasound probes in 90 seconds, enhancing infection control, patient safety, and environmental sustainability.